Commentary|Videos|October 7, 2025
Evaluation of Sigvotatug Vedotin Monotherapy in Previously Treated, Nonsquamous NSCLC
Author(s)Julia Rotow, MD, Jyoti Malhotra, MD, MPH
Fact checked by: Chris Ryan
Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin in nonsquamous NSCLC.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
SB27, a proposed pembrolizumab biosimilar, met primary end points in both a phase 1 pharmacokinetic and a phase 3 efficacy study.
OS was not improved with sigvotatug vedotin vs docetaxel in patients with pretreated, locally advanced, unresectable, or metastatic nonsquamous NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies
3
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
4
Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer
5